Dupont C, Molkhou P, Petrovic N, Fraitag B
Ann Pediatr (Paris). 1989 Feb;36(2):148-50.
Eighteen children aged 1 month to 12 years 8 months (mean age, 4.9 years) with pH-metry proven gastroesophageal reflux (GOR)-associated chronic respiratory disorders were treated with Motilium, 2 mg/kg/d in four divided doses, for three months. The incidence of each of the respiratory manifestations decreased, and their cumulative score improved significantly at the end of the treatment period. Patient daily self-assessment scores also fell, but not significantly. Twenty-one hour pH recordings showed a significant reduction in the duration of nocturnal episodes below 4 (2.8 +/- 0.9% versus 8.2 +/- 2.6%, p less than 0.05). No side effects were recorded. Domperidone provides satisfactory control of nocturnal GOR and therefore emerges as a valuable agent for the treatment of chronic GOR-associated respiratory disorders in childhood.
18名年龄在1个月至12岁8个月（平均年龄4.9岁）、经pH值测定证实患有胃食管反流（GOR）相关慢性呼吸系统疾病的儿童，接受了胃复安治疗，剂量为2毫克/千克/天，分4次服用，为期3个月。每种呼吸道表现的发生率均有所下降，且在治疗期末其累积评分显著改善。患者每日自我评估评分也有所下降，但不显著。21小时pH值记录显示，夜间pH值低于4的发作时长显著缩短（从8.2±2.6%降至2.8±0.9%，p<0.05）。未记录到副作用。多潘立酮能有效控制夜间GOR，因此成为治疗儿童慢性GOR相关呼吸系统疾病的一种有价值的药物。
